RA Treatment: When Biologic FailsMedPage TodayThe most commonly used non-TNF agents in RA are rituximab (Rituxan), a B-cell-depleting monoclonal antibody, abatacept (Orencia), a selective T-cell costimulation modulator, and tocilizumab (Actemra), a mon…
Avaxia Biologics Awarded Patent with Broad Coverage over Oral Anti-TNF …Business Wire (press release)The patent covers milk-derived anti-TNF antibodies that are orally administered within a broad dose range for the treatment of inflammatory bowel dis…
|
Caltech-Developed Method for Delivering HIV-Fighting Antibodies Proven Even …
Infection Control Today In 2011, biologists at the California Institute of Technology (Caltech) demonstrated a highly effective method for delivering HIV-fighting antibodies to mice—a treatment that protected the mice from infection by a laboratory strain of HIV delivered … |
CaptureSMB for Efficient Affinity Purification of Monoclonal AntibodiesLabmate OnlineA novel twin column counter-current chromatography process was used for the capture of monoclonal antibodies (mAbs) from clarified cell culture harvest. The process fe…
|
3 Big Pharmaceuticals Investing in Smaller Antibodies
Motley Fool Antibodies should comprise roughly half of the ten highest selling drugs over the next several years. Although they’re incredibly effective, they’re also very difficult to work with. A small biotechnology company named Ablynx in Belgium may have found … |
|
Young mother was determined to see her boys grow up
Waterloo Record In her notes, Dr. Campbell wrote “it was because of patients like Kim going through this program that Rituximab became a standard addition to chemotherapy programs now for all patients and (it) provides years more freedom from disease.” Kim was always … |
OncLive |
Six Targeted Agents for CLL Command Spotlight at ASH
OncLive Brown also expressed excitement about idelalisib, a first-in-class PI3K-delta inhibitor that—in combination with rituximab— sparked a >70% improvement in OS in patients with high-risk relapsed/refractory CLL; IPI-145, an inhibitor of PI3K-delta and … |
|
Hot Stocks Alert: Biogen Idec Inc (NASDAQ:BIIB), Synta Pharmaceuticals Corp …
Market News Call As part of the relationship, Biogen Idec will supply UCB with its portfolio of multiple sclerosis (MS) therapies and investigational candidates, including TECFIDERA®, FAMPYRA®, AVONEX®, TYSABRI®, PLEGRIDY™ and Daclizumab High-Yield Process … |
R & D Magazine |
Method for delivering HIV-fighting antibodies proven promising
R & D Magazine An illustration shows the crystal structure of the small virus used to deliver antibodies as Vectored In 2011, biologists at the California Institute of Technology (Caltech) demonstrated a highly effective method for delivering HIV-fighting antibodies … Researchers develop promising method for delivering HIV-fighting antibodiesMedical Xpress Method for Delivering HIV-Fighting Antibodies Proven Even More PromisingScienceBlog.com (blog) |
R & D Magazine |
Researchers develop promising method for delivering HIV-fighting antibodies
Medical Xpress (Medical Xpress)—In 2011, biologists at the California Institute of Technology (Caltech) demonstrated a highly effective method for delivering HIV-fighting antibodies to mice—a treatment that protected the mice from infection by a laboratory strain … Method for Delivering HIV-Fighting Antibodies Proven Even More PromisingScienceBlog.com (blog) Antibody Delivery Method Shows More Promise Against HIVDrug Discovery & Development Injected virus protects mice from HIVFuturity: Research News |